Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.
AuthorsMurphy, Derek M
Buckley, Patrick G
Foley, Niamh H
Watters, Karen M
Stallings, Raymond L
AffiliationDepartment of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Cell Line, Tumor
Promoter Regions, Genetic
MetadataShow full item record
CitationGlobal MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. 2009, 4 (12):e8154 PLoS ONE
AbstractBACKGROUND: Neuroblastoma, a cancer derived from precursor cells of the sympathetic nervous system, is a major cause of childhood cancer related deaths. The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors. METHODOLOGY: We applied MYCN chromatin immunoprecipitation to microarrays (ChIP-chip) using MYCN amplified/non-amplified cell lines as well as a conditional knockdown cell line to determine the distribution of MYCN binding sites within all annotated promoter regions. CONCLUSION: Assessment of E-box usage within consistently positive MYCN binding sites revealed a predominance for the CATGTG motif (p<0.0016), with significant enrichment of additional motifs CATTTG, CATCTG, CAACTG in the MYCN amplified state. For cell lines over-expressing MYCN, gene ontology analysis revealed enrichment for the binding of MYCN at promoter regions of numerous molecular functional groups including DNA helicases and mRNA transcriptional regulation. In order to evaluate MYCN binding with respect to other genomic features, we determined the methylation status of all annotated CpG islands and promoter sequences using methylated DNA immunoprecipitation (MeDIP). The integration of MYCN ChIP-chip and MeDIP data revealed a highly significant positive correlation between MYCN binding and DNA hypermethylation. This association was also detected in regions of hemizygous loss, indicating that the observed association occurs on the same homologue. In summary, these findings suggest that MYCN binding occurs more commonly at CATGTG as opposed to the classic CACGTG E-box motif, and that disease associated over expression of MYCN leads to aberrant binding to additional weaker affinity E-box motifs in neuroblastoma. The co-localization of MYCN binding and DNA hypermethylation further supports the dual role of MYCN, namely that of a classical transcription factor affecting the activity of individual genes, and that of a mediator of global chromatin structure.
- Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
- Authors: Murphy DM, Buckley PG, Das S, Watters KM, Bryan K, Stallings RL
- Issue date: 2011
- MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
- Authors: Charlet J, Szemes M, Malik KT, Brown KW
- Issue date: 2014 May
- SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
- Authors: Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA
- Issue date: 2015 Jul 10
- MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
- Authors: Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J
- Issue date: 2016 Feb 28
- Positive auto-regulation of MYCN in human neuroblastoma.
- Authors: Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, Nakagawara A
- Issue date: 2009 Dec 4